Passage Bio Inc.

0.33
0.00 (0.30%)
At close: Apr 17, 2025, 3:59 PM
0.37
13.39%
Pre-market: Apr 21, 2025, 05:12 AM EDT
0.30%
Bid 0.32
Market Cap 20.51M
Revenue (ttm) n/a
Net Income (ttm) -64.77M
EPS (ttm) -1.07
PE Ratio (ttm) -0.31
Forward PE -0.42
Analyst Buy
Ask 0.38
Volume 157,534
Avg. Volume (20D) 160,783
Open 0.33
Previous Close 0.33
Day's Range 0.31 - 0.36
52-Week Range 0.30 - 1.64
Beta 1.59

About PASG

Passage Bio, Inc., a genetic medicines company, develops transformative therapies for central nervous system diseases. It develops PBGM01, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GLB1 gene encoding lysosomal acid beta-galactosidase for infantile GM1; PBFT02, which utilizes an AAV1 capsid to deliver to the brain a functional granulin (GRN) and gene encoding progranulin (PGRN) for the...

Industry Biotechnology
Sector Healthcare
IPO Date Feb 28, 2020
Employees 60
Stock Exchange NASDAQ
Ticker Symbol PASG
Full Company Profile

Analyst Forecast

According to 3 analyst ratings, the average rating for PASG stock is "Buy." The 12-month stock price forecast is $6, which is an increase of 1718.18% from the latest price.

Stock Forecasts
5 months ago
+11.4%
Passage Bio shares are trading higher after the co... Unlock content with Pro Subscription